ABBVIE

The FDA approved Cobenfy, a new antipsychotic medication for schizophrenia, developed by Karuna Therapeutics. Despite its efficacy in clinical trials, concerns about insurance coverage and high list price ($22,500/year) may limit patient access. Bristol Myers Squibb, which acquired Karuna, plans to expand Cobenfy's use to bipolar disorder and Alzheimer's agitation, with ongoing studies.

J&J's Talvey shows promise in multiple myeloma trials; FDA advisory committee votes against cancer immunotherapy use in certain digestive tract cancers; AbbVie's acquisition of Cerevel Therapeutics yields positive Parkinson's drug results; Roche's Gazyva succeeds in lupus nephritis Phase 3 study; Biogen terminates agreement with Sage Therapeutics over failed essential tremor drug; Enanta Pharmaceuticals' EDP-323 shows rapid antiviral effect against RSV.

AbbVie's tavapadon met primary efficacy endpoint in Phase III TEMPO-1 trial, showing significant improvements in motor and non-motor symptoms in early-stage Parkinson’s patients. The 5-mg dose improved MDS-UPDRS parts II and III scores by 9.7 points, while the 15-mg dose improved by 10.2 points, both significantly better than placebo. Tavapadon was well-tolerated, with most side effects mild or moderate. AbbVie plans to present findings at a medical congress and use data for regulatory filing.

AbbVie's tavapadon, acquired from Cerevel Therapeutics, significantly reduced Parkinson's disease burden in Phase III TEMPO-1 trial, outperforming placebo in both 5mg and 15mg doses. The drug targets dopamine D1 and D5 receptors, potentially generating $673m by 2030 if approved.

AbbVie submits BLA for Teliso-V, an ADC targeting c-Met overexpression in previously treated nonsquamous NSCLC, with data from Phase 2 LUMINOSITY trial. Teliso-V could be the first-in-class therapy for this patient population.

The FDA approved Cobenfy, a new schizophrenia treatment by Bristol-Myers Squibb, targeting muscarinic acetylcholine receptors to avoid common dopamine-blocker side effects. Expected to be available next month at $1,850 per 30-day supply, it could generate over $6 billion in annual sales.

AbbVie’s tavapadon, acquired from Cerevel Therapeutics, significantly reduced Parkinson’s disease burden in Phase III TEMPO-1 trial, outperforming placebo in both 5mg and 15mg doses. The drug also improved motor aspects of daily living and maintained a consistent safety profile. Tavapadon is an oral dopamine receptor agonist targeting D1 and D5 receptors, potentially generating $673m by 2030 if approved.

Breast cancer treatment market employs various drugs, including chemotherapy, hormone therapies, targeted therapies, and immunotherapy. Market growth is driven by increased incidence, research advancements, early detection awareness, personalized medicine, and new drug classes. The market is projected to reach USD 49.2 billion by 2032, with major companies like Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sun Pharmaceutical, Pfizer, Teva Pharmaceutical, and AbbVie leading in innovation and geographical expansion.

OSE Immunotherapeutics reports H1 2024 results with €82.5 million income, strategic partnerships with AbbVie and Boehringer Ingelheim, and €80.7 million cash position. Clinical highlights include positive Phase 1/2 results for OSE-279 and Lusvertikimab, and the launch of the Artemia Phase 3 study for Tedopi®.

Cardurion Pharmaceuticals appoints Ron Renaud to its Board of Directors, leveraging his 25+ years of biotech experience to advance cardiovascular disease therapeutics.